GABAA receptor positive allosteric modulators

Global Ethylbenzene Market Report 2020-2025 - Styrene Production to Dominate the Market

Friday, November 27, 2020 - 7:30pm

Major factors driving the market studied are the increasing demand for styrene and increasing usage in the recovery of natural gas.

Key Points: 
  • Major factors driving the market studied are the increasing demand for styrene and increasing usage in the recovery of natural gas.
  • Strict regulations pertaining to the usage of ethylbenzene is expected to hinder the growth of the market studied.
  • Styrene production will have a positive influence on ethylbenzene market demand.
  • The ethylbenzene market is partially fragmented with the top-five players accounting for less than 30% of the market.

Marinus Pharmaceuticals Announces Four Presentations on Ganaxolone at AES2020 Virtual Annual Meeting

Monday, November 23, 2020 - 6:43pm

Some of the posters being presented by Marinus include:

Key Points: 
  • Some of the posters being presented by Marinus include:
    Intravenous Ganaxolone for the Treatment of Refractory Status Epilepticus: Results From an Open-Label, Dose-Finding, Phase 2 Study, by H. Vaitkevicius, et al.
  • Effect of Ganaxolone on Seizure Frequency Across Subpopulations of Patients with CDKL5 Deficiency Disorder: Subgroup Analyses of the Marigold Study, by E. M. Pestana-Knight, et al.
  • Pharmacokinetic-Pharmacodynamic Analysis of Oral Ganaxolone in Patients with CDKL5 Deficiency Disorder: Results From the Marigold Study, by J. Hulihan, et al.
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

DGAP-News: PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA

Thursday, November 19, 2020 - 10:07pm

- Key secondary endpoint met: remimazolam demonstrated superior hemodynamic stability compared to propofol

Key Points: 
  • - Key secondary endpoint met: remimazolam demonstrated superior hemodynamic stability compared to propofol
    - EU Phase III program completed; data to serve as basis for MAA submission in general anesthesia
    Aachen (Germany), 19 November 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces positive topline data from the pivotal remimazolam EU Phase III trial in general anesthesia.
  • Assuming approval in procedural sedation, PAION plans to submit an extension of the marketing authorization for remimazolam for general anesthesia.
  • In addition to procedural sedation and general anesthesia, based on positive Phase II study results, ICU sedation is another possible indication for remimazolam.
  • In Europe, PAION is seeking approval of remimazolam for general anesthesia and for procedural sedation.

Eisai Receives Approval for Indication Expansion of Anti-Epileptic Agent Fycompa for Use in Pediatric Patients

Monday, November 16, 2020 - 1:06am

Study 232 evaluated the pharmacokinetics, efficacy, and long-term safety of Fycompa as an adjunctive therapy in pediatric patients with epilepsy (from 2 to less than 12 years of age).

Key Points: 
  • Study 232 evaluated the pharmacokinetics, efficacy, and long-term safety of Fycompa as an adjunctive therapy in pediatric patients with epilepsy (from 2 to less than 12 years of age).
  • As we offer several treatment options in Europe, including Fycompa, Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy.
  • Eisai is conducting a global Phase III clinical study (Study 338) for the agent in patients with seizures associated with Lennox-Gastaut syndrome.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Media Inquiries: Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120
    Copyright 2020 JCN Newswire .

VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress

Thursday, November 12, 2020 - 10:25pm

We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021.

Key Points: 
  • We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021.
  • "Millions of people rely on benzodiazepines and other prescription drugs to manage symptoms of stress and anxiety.
  • CNS Pipeline Highlights and Updates:
    As in the statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, VistaGen's Phase 3 study will involve a laboratory-simulated anxiety-provoking public speaking challenge.
  • Financial Results for the Fiscal Quarter Ended September 30, 2020:
    Net loss:Net loss attributable to common stockholders for the fiscal quarter ended September 30, 2020 decreased to approximately $3.7 million compared to $5.7 million for the fiscal quarter ended September 30, 2019.

Geocann reinforces its commitment to pioneering new clinical studies with the addition of internationally recognized medical researcher

Thursday, November 12, 2020 - 4:10pm

Davidson is an internationally recognized expert on statins, novel lipid-lowering drugs, and omega-3 essential fatty acids.

Key Points: 
  • Davidson is an internationally recognized expert on statins, novel lipid-lowering drugs, and omega-3 essential fatty acids.
  • He has coordinated more than 1,000 clinical trials and published more than 250 articles for leading medical journals.
  • Davidson is well-recognized in both the medical and financial communities for his successful business acumen.
  • Geocann owns a robust intellectual property portfolio, including the worldwide exclusivity for cannabinoids, terpenes, and flavonoids formulated with VESIsorb.

DGAP-News: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2020

Wednesday, November 11, 2020 - 7:01am

In the U.S., the FDA (Food & Drug Administration) granted market approval of BYFAVOTM (remimazolam) for procedural sedation in July 2020.

Key Points: 
  • In the U.S., the FDA (Food & Drug Administration) granted market approval of BYFAVOTM (remimazolam) for procedural sedation in July 2020.
  • In October 2020, the Drug Enforcement Administration (DEA) designated BYFAVO(TM) as a Schedule IV medicine, which was a prerequisite for launch.
  • The overall evaluation of opportunities and risks has not changed significantly in the first nine months of 2020.
  • PAION confirms its financial outlook for the current fiscal year announced on 12 August 2020 with the publication of the half-year results for 2020.

Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients

Tuesday, November 10, 2020 - 11:47am

INOmax is indicated for the treatment of term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.

Key Points: 
  • INOmax is indicated for the treatment of term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.
  • "We hope this retrospective chart review will help to further extend our understanding of the use of inhaled nitric oxide," said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer atMallinckrodt.
  • Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia.
  • This release includes forward-looking statements concerning inhaled nitric oxide ("iNO") and the Company's INOmaxproduct, including statements with regard to the proposed chart study, the potential impact of iNO on patients and anticipated benefits associated with its use.

China Sevoflurane Markets Report 2015-2019 & 2020-2024: Major Players are Shanghai Hengrui Pharmaceutical, Maruishi, Baxter and Lunan Better Pharmaceutical

Monday, November 9, 2020 - 2:45pm

DUBLIN, Nov. 9, 2020 /PRNewswire/ -- The "Investigation Report on Sevoflurane in China, 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 9, 2020 /PRNewswire/ -- The "Investigation Report on Sevoflurane in China, 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • In 2007 and 2008, the Chinese government approved the inhaled solution sevoflurane of Shanghai Hengrui Pharmaceuticals and Lunan Better Pharmaceutical to go public in China.
  • According to this market research, the major market shareholders in China are Shanghai Hengrui Pharmaceutical Co., Ltd., Maruishi, Baxter and Lunan Better Pharmaceutical Co., Ltd.
  • 2 Analysis of Sevoflurane Sales in China, 2015-2019
    2.1 Sales Value of Sevoflurane in China, 2015-2019
    2.1.1 Overall Sales value of Sevoflurane in China, 2015-2019
    2.1.2 Sales Value of Sevoflurane in different regions of China, 2015-2019
    2.2 Sales Volume of Sevoflurane in China, 2015-2019
    2.2.1 Overall Sales Volume of Sevoflurane in China, 2015-2019
    2.2.2 Sales Volume of Sevoflurane in Different Regions of China, 2015-2019
    2.3 Market Share of Sevoflurane by Dosage Form in China, 2015-2019
    3 Major Sevoflurane Manufacturers in Chinese Market, 2015-2020
    3.1 Shanghai Hengrui Pharmaceutical Co., Ltd.
    3.1.1 Profile of Shanghai Hengrui Pharmaceutical Co., Ltd.
    3.1.2 Sales value and volume of Shanghai Hengrui Pharmaceutical Co., Ltd.'s sevoflurane in China 2019-2020
    3.2.1 Profile of Maruishi Pharmaceutical Co., Ltd.
    3.3 Lunan Better Pharmaceutical Co., Ltd.
    3.3.1 Profile of Lunan Better Pharmaceutical Co., Ltd.
    3.3.2 Sales value and volume of Lunan Better Pharmaceutical Co., Ltd.'s sevoflurane in China 2019-2020
    4 Reference Price of Sevoflurane in Different Regions of China, 2019-2020
    4.2 Average Price of Shanghai Hengrui Pharmaceutical Co., Ltd.'s Sevoflurane in China
    4.2.2 Prices of Shanghai Hengrui Pharmaceutical Co., Ltd.'s Sevoflurane in different regions of China
    4.4 Average Price of Lunan Better Pharmaceutical Co., Ltd.'s Sevoflurane in China
    4.4.2 Prices of Lunan Better Pharmaceutical Co., Ltd.'s Sevoflurane in different regions of China
    5 Prospects of Sevoflurane in China, 2020-2024
    Chart Sales Value of Sevoflurane in China, 2015-2019
    Chart Sales volume of Sevoflurane in China, 2015-2019
    Chart Market Share of Top 6 Sevoflurane Manufacturers in Sales Value, 2015-2019
    Chart Market Share and Sales Value of Maruishi in China, 2015-2019
    Chart Market Share and Sales Value of Shanghai Hengrui Pharmaceutical in China, 2015-2019
    Chart Market Share and Sales Value of BAXTER in China, 2015-2019
    Chart Price of Maruishi's Sevoflurane in Different Regions of China, 2019-2020
    Chart Price of Shanghai Hengrui Pharmaceutical's Sevoflurane in Different Regions of China, 2019-2020
    Chart Forecast on Sevoflurane Market Size in China, 2020-2024
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients

Monday, November 9, 2020 - 1:09pm

Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.

Key Points: 
  • Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.
  • Status epilepticus is associated with irreversible neurologic damage and death, both of which largely depend on the seizure duration before initial treatment, stated Barry Frankel, Chief Business Officer and co-founder of Sedor.
  • SESQUIENT the first and only FDA-approved room temperature stable fosphenytoin could help health care providers quickly treat status epilepticus patients and potentially reduce hospital costs associated with this condition.
  • The companys lead product, SESQUIENT, has received FDA approval for the treatment of status epilepticus.